 EMERYVILLE, Calif., Sept. 24, 2021 GLOBE NEWSWIRE -- 4D Molecular Therapeutics Nasdaq: FDMT, a clinical-stage gene therapy company harnessing the power of directed evolution for targeted gene therapies, announced a late-breaking presentation of preliminary clinical data from the on-going 4D-125 Phase 12 trial in patients with X-Linked Retinitis Pigmentosa XLRP will be presented at the upcoming Annual Society of Retina Specialists Annual Meeting ASRS 2021 that will take place in San Antonio, TX on October 8-12, 2021. 